Top Markets
#1 TENDIES TENDIES +47.26%
#2 Cash Cat Cash Cat +32.66%
#3 Threshold Network Threshold Network +20.34%
#4 OSK OSK +15.77%
#5 Asteroid Shiba Asteroid Shiba +12.66%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 Magma Finance Magma Finance +12.59%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.14%
#9 Kite Kite +10.97%
#10 MarsCoin MarsCoin +10.48%
Coin of the day
TENDIES TENDIES
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Clasificación en acciones #16560
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Precio por acción
$0.23346537
Capitalización bursátil
$285.87M
Cambio (1 día)
6.41%
Cambio (1 año)
-63.91%
País
CN
Comercio AIM Vaccine Co., Ltd. (6660)

Categoría

Healthcare
Historial del precio de la acción de AIM Vaccine Co., Ltd. (6660)
Precio más alto de cierre: $0.23 el 2026-09-01

Precio más bajo de cierre: $2.84 el 2022-10-01
Historial del precio de la acción de AIM Vaccine Co., Ltd. desde 2022 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -13.76%
2025 -48.14%
2024 -16.05%
2023 -68.54%
2022 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.15 36.70%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 45.33%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $153.87 536.09%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.21 -10.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $755.10 7.83%
CH